Assembly BiosciencesASMB
Recorded

Assembly Biosciences 3rd Annual Guggenheim Healthcare Innovation Conference

Review the key takeaways and the transcript of this earnings call.

PeriodFY 0Duration25 minParticipants5

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Vamil DivanBiopharmaceutical Analyst

Okay. All right, I think we're ready to get started. Thanks everyone for joining us again this year for the Guggenheim Healthcare Innovation Conference here on day two. I'm Vamil Divan, one of the biopharma analysts here at Guggenheim. Next to me from the Guggenheim side, we have Evan Wang from the team. Next up from the corporate side in this room, we have the Assembly Biosciences team. Going down the stage here, Bill Delaney, the CSO, Anuj Gaggar, the CMO, and Jason Okazaki, the CEO. Thanks so much for giving us the time and coming to the conference again this year. Obviously, a lot going on with the company over the last several months.

Vamil DivanBiopharmaceutical Analyst

Maybe, Jason, I'll just turn to you first if you want to just share kind of an overview on the progress you've made, and then we'll sort of walk our way through some of the key developments on the programs.

Jason OkazakiCEO

Sure. Thanks, Vamil, and Evan, good to see you again. Thanks for having us to the conference. Look, 2026 has been a pretty big execution year for us. I think 2025, heavy on data, and what you'll see is 2027, specifically starting the second half, is going to be another data-heavy year. As far as recent highlights, we just opted into our 40/60 share of the cost profit split with Gilead on the HSV-2 program, which we think is positive news. Also, you might recall, Gilead also announced as part of that study, they're going to explore potentially a dual HIV/HSV PrEP, which is certainly an interesting angle I'm sure we'll talk about.

Jason OkazakiCEO

Just last week, we initiated the phase II for Hep Delta for ABI-6250, which we're excited about, and that will be probably the first of the datasets that'll come up next year, second half, called Q3, Q4. We also saw that Gilead filed on ClinicalTrials.gov the GS-1179 phase II trial head-to-head against Valtrex. You're looking at the expected timing of that. Of course, they control that program, but hopefully we'll get some data on that in the next year as well. Early in 2027, along the lines of ABI-6250, our small molecule oral entry inhibitor, in addition to the Delta study, we'll be initiating the PBC/PSC study early next year with that dataset expected first half of 2028. So next year is going to be quite a heavy data year, especially starting second half and going into 2028, so pretty excited about that.

Vamil DivanBiopharmaceutical Analyst

Okay, great. Let's start with genital herpes. I think, obviously now Gilead leading, but still very important from an Assembly perspective. Maybe if you can just talk about the broader opportunity, what it means for Assembly, especially with the 40/60 relationship.

Jason OkazakiCEO

Yeah, I mean, we've always had the market analysis for just HSV-2, and this is obviously excluding the dual PrEP because that's a new wrinkle for us. But that, in our minds, is a $2 billion plus market, and we get there from two ways. One is top-down epidemiology. You've got 2 million patients roughly split in the U.S. and then 2 million in EU as well. We've also done a very detailed bottoms-up analysis with the University of Washington at a poster we published at ESMO last year. From that, we looked at ICD-10 codes, we looked at Valtrex scripts that are 90 days or longer, and it kind of created what we think of as the floor of the market.

Jason OkazakiCEO

From that extrapolation, we get to about 1.3, 1.4 million patients in the U.S. with recurrent genital herpes, of which there's probably about 800,000 on chronic therapy through Valtrex. Of course, we expect and hope that ABI-1179 will be superior to Valtrex on efficacy, but also certainly more convenient at a once-weekly dosing. The pricing we've tested with payers in the past, given that profile, is we can expect a premium to brand of Valtrex, which is about $5,500. Just imagine we tested the premium somewhere between $5,500 and the $10,000 range. Doing pretty simple math, even if you got half of that existing 800,000 patient market, that's multi-billion dollars right there. The history of Dr. Vaughn, particularly our team, knowing and living through HIV, HCV development at Gilead, is that the better the molecule, the more people seek treatment.

Jason OkazakiCEO

We really look at that 1.4 million patients in the U.S. as a floor for the market potential. We know there's a very high unmet medical need, talking to KOLs, talking to patients, so we're excited to see Gilead move this program as fast as possible.

Vamil DivanBiopharmaceutical Analyst

Okay, great. We do get a lot of questions now on the competitive landscape. You mentioned Valtrex. Maybe you could just talk about how you look to differentiate against that older product, but also what else you are seeing emerging in the space.

Jason OkazakiCEO

Yeah, certainly exciting in the space. Pritelivir just got approved on a very niche dual-resistant, acyclovir-resistant population. Again, a very small group within the overall patient group. We are hopeful, based on the current data we have for GS-1179, and again, this is up to Gilead, but we should be able to cover that patient base as well, as well as a broader HSV-2 population. Maybe, Anuj, if you want to talk about what we expect to achieve versus Valtrex.

Anuj GaggarCMO

Yeah, I think when we look at the preclinical profile, we know that our molecules or Gilead's molecules, GS-1179, are significantly more potent than Valtrex. Pritelivir actually is a really nice intermediate medication to look at too from a head-to-head comparison, because pritelivir went head-to-head against Valtrex in a phase II study and beat Valtrex with a 50% or more reduction in lesions and in shedding. With our preclinical profile to be superior to pritelivir, we really expect to have a high probability of success to beat Valtrex in that phase II study, so we are excited for that readout from Gilead.

Vamil DivanBiopharmaceutical Analyst

Okay. The phase II is now posted. We saw this recently, about 300 patients, four-plus recurrences per year, shedding is primary endpoint. Just walk us through the design and what we should think about in terms of enrollment and then timing of the actual data.

Anuj GaggarCMO

Yeah, I think the design as we see it on ClinicalTrials.gov is a lot like what was in our minds previously for this molecule. It looks like three arms, as you said, a high dose of GS-1179 in arm one, a low dose in arm two of GS-1179, and then Valtrex in arm three, using the patient population, like you said, which is similar to what we had tested in phase I-B, which is patients who have between four and nine recurrences per year, either on or not on a nuc at the time. The main endpoint, like you said, is shedding, so a 28-day period within that 12-week dosing period in which they will do viral swabs to look at shedding, and then overall looking at lesions.

Anuj GaggarCMO

There are many ways to look at that data, and I think you will see those secondary endpoints are just showing you the many ways you can look at that data, from numbers of lesion days, number of days being lesion-free, et cetera. But I think in the end, the goal is to really benchmark versus Valtrex and get the right dose and then move those forward into phase III.

Vamil DivanBiopharmaceutical Analyst

Okay. Maybe one more we will do on the- Sorry, please sign and I will turn over to Evan Wang on ABI-6250. But you talked about prevention and sort of the new wrinkles or the story here, just how should people think about the opportunity there? It does seem like a big potential upside driver. Maybe you could just talk about kind of your views there.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day